Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock

Critical Care Medicine

Volumn 34, Issue 4, 2006, Pages 980-985

  Warrillow, Stephen ^a   Egi, Moritoki ^a   Bellomo, Rinaldo ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

Adenosine triphosphate sensitive potassium channel; Glibenclamide; Norepinephrine; Sepsis; Septic shock; Sulfonylurea

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; LACTIC ACID; NORADRENALIN; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT;

AGED; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GLYBURIDE; HUMANS; MALE; NOREPINEPHRINE; PILOT PROJECTS; POTASSIUM CHANNEL BLOCKERS; SHOCK, SEPTIC;

EID: 33645828012     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000206114.19707.7C     Document Type: Article

References (37)

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
2. Brun-Buisson C, Doyon F, Carlet J, et al: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274:968-974
3. Brun-Buisson C, Meshaka P, Pinton P, et al: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588
4. Annane D, Egerter P, Jars-Guincestre MC, et al: Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172
5. Alberti C, Brun-Buisson C, Goodman SV, et al: Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003; 168:77-84
6. Wilson RF, Thal AP, Kindling PH, et al: Hemodynamic measurements in septic shock. Arch Surg 1965; 91:121-129
7. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280-287
8. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595
9. Martin C, Viviand X, Leone M, et al: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28:2758-2765
10. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
11. Sessler CN, Perry JC, Varney KL: Management of severe sepsis and septic shock. Curr Opin Crit Care 2004; 10:354-363
12. Thiermermann C: Nitric oxide and septic shock. Gen Pharmacol 1997; 29:159-166
13. Wolkow PP: Involvement and dual effects of nitric oxide in septic shock. Inflamm Res 1998; 47:152-166
14. Ochoa JB, Udekwu AO, Billiar TR, et al: Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991; 214:621-626
15. Titheradge MA: Nitric oxide in septic shock. Biochim Biophys Acta 1999; 1411:437-455
16. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125
17. Brackett DJ, Schaefer CF, Wilson MF: The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv Shock Res 1983; 9:147-156
18. + channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992; 89:2071-2074
19. ATP-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 1997; 272:H688-H694
20. + channels. Biochim Biophys Acta 1999; 1461:285-305
21. Cook NS: The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci 1988; 9:21-28
22. Ashcroft FM: Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci 1988; 11:97-118
23. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000; 49(10 Suppl 2):3-6
24. Gardiner SM, Kemp PA, March JE, et al: Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: Effects of pre- or post-treatment with glibenclamide. Br J Pharmacol 1999; 128:1772-1778
25. Geisen K, Vegh Am, Krause E, et al: Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996; 28:496-507
26. Zhao KS, Xuliang JL, Huang Q, et al: New approach to treatment of shock: Restitution of vasoreactivity. Shock 2002; 18:189-192
27. Vanelli G, Hussain SNA, Dimori M, et al: Cardiovascular responses to glibenclamide during endotoxaemia in the pig. Vet Res Commun 1997; 21:187-200
28. Vanelli G, Hussain SNA, Aguggini G: Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 1995; 80:167-170
29. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
30. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344; 10:699-709
31. Caswell A, Harvey A, Bellantonio J (Eds): eMIMS. Available at: http://mims.hcn.net.au. Accessed January 14, 2005
32. Shenfield G, Colman P, Diamond T, et al: Getting to know your drugs: Sulphonylureas. In: eTherapeutic Guidelines: Endocrinology. Available at: http://etg.hcn.net.au/. Accessed January 14, 2005
33. Rang HP, Dale MM: The circulation. In: Pharmacology. Second Edition. London, Churchill Livingston, 1992, pp 346-368
34. Singer M, Coluzzi F, O'Brien A, et al: Reversal of life-threatening, drug related potassium channel syndrome by glibenclamide. Lancet 2005; 365:1873-1875
35. ATP channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro. Br J Pharmacol 2005; 144:367-375
36. ATP channel inhibitors determines their ability to inhibit the iNOS-mediated relaxation in rat aorta. Cardioavasc Res 2002; 56:154-163
37. Presier JC, Zhang H, Debelle F, et al: Hemodynamic effects of glibenclamide during endotoxemia: Contrasting findings in vitro versus in vivo. Shock 2003; 19:223-228